Vor Biopharma Inc.

0.59
-0.04 (-6.94%)
At close: Apr 03, 2025, 3:59 PM
0.61
3.86%
After-hours: Apr 03, 2025, 05:08 PM EDT
-6.94%
Bid 0.59
Market Cap 73.78M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1.7
PE Ratio (ttm) -0.35
Forward PE -1.21
Analyst Buy
Ask 0.64
Volume 323,938
Avg. Volume (20D) 463,701
Open 0.62
Previous Close 0.63
Day's Range 0.57 - 0.62
52-Week Range 0.57 - 2.23
Beta -0.41

About VOR

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, an...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 159
Stock Exchange NASDAQ
Ticker Symbol VOR
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for VOR stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 1761.57% from the latest price.

Stock Forecasts
3 months ago
+51.55%
Vor Bio shares are trading higher after the compan... Unlock content with Pro Subscription
3 months ago
+26.89%
Vor Biopharma shares are trading higher after the company announced it will present data on its AML therapy at the ASH 2024 annual meeting.